// App-Quantinova.ai

5551 : Potent oral ERAP1 inhibitors modify the immunopeptidome in vivo and are novel immunotherapy agents

Researchers

Presenter

  • Jamie Ware

Principal Investigators

  • Patrick McIntyre

  • Kristopher Clark

  • Carmen Tong

  • Jason Shiers

  • Elisa Lori

  • Camila de Almeida

  • Emma Reeves

  • Henry Leonard

  • Alihussein Remtulla

  • Michael Ford

  • Nicola Ternette

  • Fergus Poynton

  • Edd James

  • Lesley Young

  • Martin Quibell

  • Peter I. Joyce

Medical Centers

  • Sygnature Discovery, Nottingham, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Certara, United Kingdom

  • Charles River Laboratories, Portishead, UK

  • MS Bioworks, MI

  • University of Oxford, Oxford, United Kingdom

  • Grey Wolf Therapeutics Ltd, Oxford, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ankylosing spondylitis

  • Solid malignancies

Biomarkers

  • Cluster of differentiation 8A

  • Interferon-gamma

Drug/Treatment

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved